VX12-770-112: A Phase 3, TWO-Arm, Rollover Study to Evaluate the Safety of Long-Term Ivacaftor Treatment in Subjects 6 Years of Age and Older with Cystic Fibrosis and a Non-G551D CFTR Mutation

Project: Research project

Project Details

StatusFinished
Effective start/end date9/1/12 → 8/31/13

Funding

  • Vertex Pharmaceuticals Incorporated (VX12-770-112)